Lv1
80 积分 2025-08-25 加入
Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies
3个月前
已完结
Characterization of bridging therapies in clinical trials leading to FDA approval of CAR‐T cell therapies
3个月前
已完结
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy
3个月前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
3个月前
已完结
MM-522 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
3个月前
已完结
P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
3个月前
已完结
P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium
4个月前
已完结
P-028 Characteristics of Bridging Therapy and Impact of Pre-lymphodepletion Tumor Burden on Clinical Outcomes of Idecabtagene Vicleucel
4个月前
已完结
P-011 Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/ refractory multiple myeloma are associated with pre-CAR-T bridging therapies
4个月前
已关闭
MM-522 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma
4个月前
已完结
皖公网安备34019202002308
